Skip to content
Bored Studies
RecruitingPhase 3

A Phase 3 Study to Evaluate the Safety and Efficacy L606 in Participants With PH-ILD

Liquidia Technologies, Inc. · NCT07285655

View Study & Apply (opens in a new tab)

Opens the official ClinicalTrials.gov record, with the study team’s contacts. Bored Studies doesn’t enroll anyone.

Key facts

Compensation
Not posted. Ask the study team before screening.
Who can join
Ages 18–80 · All sexes
Healthy volunteers
Not accepted (a condition is required)
Study type
Interventional · Phase 3
Target enrollment
344
US sites recruiting
13
Study start
April 23, 2026
Record last updated
October 14, 2026

Status re-checked against ClinicalTrials.gov within the last 12 hours.

What the study is about

The purpose of this study is to find out if L606 is safe and if it helps people with high blood pressure in the lungs (pulmonary hypertension) caused by interstitial lung disease (PH-ILD, WHO Group 3). One of the main ways the study will check this is by seeing if people can walk further in six minutes (called the "six-minute walk test"). Another important (secondary) goal is to see how long it takes for PH-ILD to get worse while people are taking L606. One way the study will measure this is by looking at the distance people walk at different times in the study on different doses of L606. Throughout the study, doctors will also closely monitor for any side effects people have to make sure L606 is safe. People who decide to join this study will be randomly (like tossing a coin) placed into one of two groups: one group will get L606 and the other group will get a placebo, which will look like L606 but will not contain any active medicine. At the end of the initial blinded portion of the study, study participants may have the opportunity to enroll in an open-label extension portion of the study where all participants will receive L606.

Being studied: L606; Placebo

Conditions: Pulmonary Hypertension Due to Lung Disease (Disorder)

Eligibility criteria

Copied from the official record. The study team makes the final decision at screening.

Show full criteria

Inclusion Criteria

  • Participant is between 18 years to 80 years old.
  • Has a confirmed diagnosis of ILD based on High Resolution Computed Tomography (HRCT) chest imaging.
  • Evidence of PH as demonstrated from Right Heart Catheterization (RHC) with the following hemodynamic parameters:
  • Pulmonary vascular resistance (PVR) ≥ 320 dynes.sec/cm5 (i.e. 4 Woods Units (WU)), and
  • Mean Pulmonary Artery Pressure (mPAP) of ≥ 25 mmHg, and
  • - Pulmonary capillary wedge pressure (PCWP) or Left-Ventricular End Diastolic Pressure (LVEDP) of ≤ 15 mmHg.
  • FEV1/FVC (ratio) > 0.70.
  • 6-minute walk distance ≥ 150 meters

Exclusion Criteria

  • PH in the updated WHO Classification Groups 1, 2, 4, or 5.
  • Has evidence of clinically significant left-sided heart disease as defined by echocardiography.
  • Participants with history of persistent/permanent or uncontrolled atrial fibrillation.
  • Participants with severe obstructive sleep apnea.
  • Has experienced exacerbation of underlying lung disease or active respiratory infection requiring antibiotics.
  • Initiation of pulmonary rehabilitation.

Note: Other protocol defined inclusion/exclusion criteria may apply.

Recruiting US locations

  • Dignity Health - St. Joseph's Hospital and Medical Center

    Phoenix, AZ 85013

    Site contact: Jennifer Guthrie · jennifer.guthrie@commonspirit.org

  • Arizona Pulmonary Specialists, Ltd.

    Scottsdale, AZ 85258

  • David Geffen School of Medicine at UCLA

    Los Angeles, CA 90095-1690

    Site contact: Jaclene Torres · jaclenetorres@mednet.ucla.edu

  • University of California, San Francisco

    San Francisco, CA 94143

    Site contact: Sarah Mettias · sarah.mettias@ucsf.edu

  • University of Colorado Hospital

    Aurora, CO 80045

    Site contact: Johan Allingmon · johan.allingmon@cuanschutz.edu

  • National Jewish Hospital

    Denver, CO 80206

    Site contact: Skyler Chenaille · chenailles@njhealth.org

  • Tampa General Hospital

    Tampa, FL 33606

    Site contact: Elisabeth Ballans · eballans@tgh.org

  • Northwestern University

    Chicago, IL 60611

  • St. Vincent Cardiovascular Research Institute

    Indianapolis, IN 46260

    Site contact: Morgan Arnold · 317-338-9337 · morgan.arnold@ascension.org

  • NYU Langone Health

    New York, NY 10016

    Site contact: Anabela Barroso · anabela.barroso@nyulangone.org

  • University of Rochester Medical Center

    Rochester, NY 14642

    Site contact: Andrew Mintz · andrew_mintz@urmc.rochester.edu

  • Summit Health

    Bend, OR 97701

    Site contact: Madison Cox · 541-706-5339 · mklinskicox@summithealth.com

  • Medical University of South Carolina- Nexus Research Clinic

    Charleston, SC 29425

    Site contact: Ashley Ward · 843-792-4349 · jonesash@musc.edu

Study contacts (from the official record)

  • Liquidia Point of Contact · 1-888-241-6906 · LiquidiaStudies@liquidia.com
All heart & blood pressure studies in Arizona →
A Phase 3 Study to Evaluate the Safety and Efficacy L606 in… (NCT07285655) | Bored Studies